Onxeo to Attend Key Investor and Scientific Conferences

Paris (France), September 11, 2019 – 5.45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, in particular against rare or resistant cancers, today announced that its management team will attend the following key investor and scientific conferences in the coming months:

  • Investir Day

October 3, 2019, Paris, France

A new event providing shareholders and retail investors with the opportunity to meet and discuss with executives of listed companies. A masterclass session by Judith Greciet, CEO of Onxeo, is scheduled during the event.

  • The Galien Medstartup 2019

October 24, 2019, in New York, NYC, United-States

The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Its vision is to be the catalyst for the development of the next generation of innovative treatment and technologies that will impact human health and save lives.

 

  • AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 26-30, 2019, in Boston, MA, United-States

The premier international meeting featuring novel cancer therapeutics organized by the American Association for Cancer Research (AACR), the National Cancer Institute (NCI) and the European Organisation for Research and Treatment of Cancer (EORTC).

  • Direct Dirigeants event with Les Echos – Investir

November 6, 2019, in Paris, France

Presentation by Judith Greciet, CEO of Onxeo, to individual investors and shareholders.

  • 2nd Annual DNA Damage Response Therapeutics Summit

January 29-31, 2019, in Boston, MA, United-States

The Summit brings together the leading pharma and biotech companies accelerating the development of DNA repair pathway inhibitors, to optimize drug discovery, broaden patient population and generate greater efficacy.

190911_PR_Onxeo_Conferences H2 2019